ResMed Inc. vs Weyerhaeuser Company Common Stock — how do they compare? ResMed Inc. trades at $236.19 (market cap $33.09B), while Weyerhaeuser Company Common Stock trades at $19.04 (market cap $13.62B). The key difference: ResMed Inc. is far larger — about 2.4× Weyerhaeuser Company Common Stock's market cap, and Weyerhaeuser Company Common Stock pays the higher dividend (4.44%). Which is the better fit depends on your goals.
| RMD | WY | |
|---|---|---|
Market Cap | $33.09B | $13.62B |
Volume | 1,019,685 | 8,637,043 |
Sector | Health | Real Estate |
52-Week High | $275.96 | $27.10 |
52-Week Low | $182.82 | $18.47 |
Typical Hold Time | 51 Days | — |
Enterprise Value | $32.45B | $18.54B |
Dividend Yield | 1.12% | 4.44% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $235.04, up 0.19% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $243.56. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding expectations. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%, while cash flow from operations reached $1.75B. Recent news highlights upcoming Q1 2027 earnings and a Morgan Stanley conference presentation focusing on growth targets.
The outlook for RMD is positive, driven by consistent earnings outperformance, high profitability, and institutional buying interest. Key opportunities include market share gains and product innovation in sleep therapy, though risks involve competitive pressures and ongoing legal investigations. The stock's current valuation metrics, including a P/E of 22.56, appear reasonable relative to growth, supporting a constructive view for investors seeking exposure to healthcare equipment.
Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.
Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.
Read more on WY →